The psychedelic renaissance, a resurgence of interest in psychedelic medicine after decades of repression, is driven by scientific innovation and a flood of venture capital investment. Interviews with industry stakeholders reveal that private funding shapes research practices and public perceptions, creating tension between idealistic and capitalist narratives. The analysis highlights a paradox: psychedelic mysticism resists the rigid criteria of evidence-based medicine, challenging the psychopharmacological paradigm. The findings call for critical public engagement with the ethical dimensions of integrating psychedelics into mainstream medicine, focusing on the emergence of grey areas in capital networks where cultural and political values are rearranged.
The commercialization of psychedelics like psilocybin, LSD, and MDMA for mental health treatment blurs the line between impartial science and profit-driven industry. Based on in-depth interviews with stakeholders, the study reveals how venture capitalists not only fund research but also provide regulatory and industry knowledge, creating ethical dilemmas for scientists. Researchers' reluctance to disclose personal psychedelic experiences during interviews signals a shift from an illegality paradigm to one of intellectual property. The findings suggest that ethical dynamics in scientific practice must be reconsidered, particularly how public and private funders shape researchers' priorities.